Mesenchymal Stem Cells Contribute to Tumor Cell Proliferation by Direct Cell-Cell Contact Interactions

REFERENCES

• Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S.; Marshak, D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 5411(284), 143–147.
   Google Scholar
• Prockop, D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 5309(276), 71–74.
   Google Scholar
• Le Blanc, K.; Rasmusson, I.; Sundberg, B.; Gotherstrom, C.; Hassan, M.; Uzunel, M.; Ringden, O. Treatment of severe acute graft-versus-host disease with third-party haploidentical mesenchymal stem cells. Lancet 2004, 9419(363), 1439–1441.
   Google Scholar
• Le Blanc, K.; Frassoni, F.; Ball, L.; Locatelli, F.; Roelofs, H.; Lewis, I.; Lanino, E.; Sundberg, B.; Bernardo, M.E.; Remberger, M.; Dini, G.; Egeler, R.M.; Bacigalupo, A.; Fibbe, W.; Ringden, O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase-II study. Lancet 2008, 9624(371), 1579–1586.
   Google Scholar
• Nauta, A.J.; Fibbe, W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 10(110), 3499–3506.
   Google Scholar
• Djouad, F.; Plence, P.; Bony, C.; Tropel, P.; Apparailly, F.; Sany, J.; Noel, D.; Jorgensen, C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 10(102), 3837–3844.
   Google Scholar
• Djouad, F.; Bony, C.; Apparailly, F.; Louis-Plence, P.; Jorgensen, C.; Noel, D. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 2006, 8(82), 1060–1066.
   Google Scholar
• Ramasamy, R.; Lam, E.W.; Soeiro, I.; Tisato, V.; Bonnet, D.; Dazzi, F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 2007, 2(21), 304–310.
   Google Scholar
• Kawada, H.; Fujita, J.; Kinjo, K.; Matsuzaki, Y.; Tsuma, M.; Miyatake, H.; Muguruma, Y.; Tsuboi, K.; Itabashi, Y.; Ikeda, Y.; Ogawa, S.; Okano, H.; Hotta, T.; Ando, K.; Fukuda, K. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004, 12(104), 3581–3587.
   Google Scholar
• Ren, C.; Kumar, S.; Chanda, D.; Chen, J.; Mountz, J.D.; Ponnazhagan, S. Therapeutic potential of mesenchymal stem cells-producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 2008, 9(26), 2332–2338.
   Google Scholar
• Studeny, M.; Marini, F.C.; Champlin, R.E.; Zompetta, C.; Fidler, I.J.; Andreeff, M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002, 13(62), 3603–3608.
   Google Scholar
• Beckermann, B.M.; Kallifatidis, G.; Groth, A.; Frommhold, D.; Apel, A.; Mattern, J.; Salnikov, A.V.; Moldenhauer, G.; Wagner, W.; Diehlmann, A.; Saffrich, R.; Schubert, M.; Ho, A.D.; Giese, N.; Buchler, M.W.; Friess, H.; Buchler, P.; Herr, I. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 2008, 4(99), 622–631.
   Google Scholar
• Kinnaird, T.; Stabile, E.; Burnett, M.S.; Lee, C.W.; Barr, S.; Fuchs, S.; Epstein, S.E. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004, 5(94), 678–685.
   Google Scholar
• Annabi, B.; Naud, E.; Lee, Y.T.; Eliopoulos, N.; Galipeau, J. Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors. J Cell Biochem 2004, 6(91), 1146–1158.
   Google Scholar
• Klein, E.; Klein, G.; Nadkarni, J.S.; Nadkarni, J.J.; Wigzell, H.; Clifford, P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 1968, 7(28), 1300–1310.
   Google Scholar
• Roorda, B.D.; ter Elst, A.; Diks, S.H.; Meeuwsen-de Boer, G.J.; Kamps, W.A.; de Bont, E.S.J.M. PTK787/ZK 222584 inhibits tumor growth-promoting mesenchymal stem cells: kinase activity profiling as powerful tool in functional studies. Cancer Biol Ther 2009, 13(8), (Epub ahead of print).
   Google Scholar
• Vermeulen, P.B.; Gasparini, G.; Fox, S.B.; Toi, M.; Martin, L.; McCulloch, P.; Pezzella, F.; Viale, G.; Weidner, N.; Harris, A.L.; Dirix, L.Y. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996, 14(32A), 2474–2484.
   Google Scholar
• Wood, J.M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K.H.; Schneider, M.R.; Drevs, J.; Martiny-Baron, G.; Totzke, F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000, 8(60), 2178–2189.
   Google Scholar
• Kyriakou, C.A.; Yong, K.L.; Benjamin, R.; Pizzey, A.; Dogan, A.; Singh, N.; Davidoff, A.M.; Nathwani, A.C. Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model. J Gene Med 2006, 3(8), 253–264.
   Google Scholar
• Spaeth, E.L.; Dembinski, J.L.; Sasser, A.K.; Watson, K.; Klopp, A.; Hall, B.; Andreeff, M.; Marini, F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 2009, 4(4), e4992.
   PubMed Web of Science ®Google Scholar
• Damiano, J.S.; Cress, A.E.; Hazlehurst, L.A.; Shtil, A.A.; Dalton, W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 5(93), 1658–1667.
   Google Scholar
• Matsunaga, T.; Takemoto, N.; Sato, T.; Takimoto, R.; Tanaka, I.; Fujimi, A.; Akiyama, T.; Kuroda, H.; Kawano, Y.; Kobune, M.; Kato, J.; Hirayama, Y.; Sakamaki, S.; Kohda, K.; Miyake, K.; Niitsu, Y. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003, 9(9), 1158–1165.
   PubMed Web of Science ®Google Scholar
• Galmiche, M.C.; Koteliansky, V.E.; Briere, J.; Herve, P.; Charbord, P. Stromal cells from human long-term marrow cultures are mesenchymal cells that differentiate following a vascular smooth muscle differentiation pathway. Blood 1993, 1(82), 66–76.
   Google Scholar
• Wu, Y.; Chen, L.; Scott, P.G.; Tredget, E.E. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007, 10(25), 2648–2659.
   Google Scholar
• Roorda, B.D.; ter Elst, A.; Kamps, W.A.; de Bont, E.S. Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived cells to tumor microenvironments with special focus on mesenchymal stem cells. Crit Rev Oncol Hematol 2009, 3(69), 187–198.
   Google Scholar
• Mueller, M.M.; Fusenig, N.E. Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 11(4), 839–849.
   Google Scholar